drugset / Trial / NCT05628272

MNCs for Bone Marrow Failure After Malignant Diseases Children Chemotherapy

NCT05628272 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

This project aims to investigate the therapeutic and repair effects of cord blood mononuclear cells (MNCs) on bone marrow failure after chemotherapy in children with malignant diseases. It is planned to collect 20 malignant children with bone marrow failure after chemotherapy and randomly divide them into two groups. The umbilical cord blood mononuclear cells were injected, ≥1×10\^8 per infusion, once a week, and the recovery time of peripheral blood leukocytes, neutrophils, platelets and hemoglobin was observed. According to the recovery of myelosuppression, stop when the peripheral blood reaches leukocytes\>1×10\^9/L, neutrophils\>0.5×10\^9/L, platelets\>25×10\^9/L, and hemoglobin\>60g/L at the same time. Use, share 1-4 times. Statistical software was used to compare the changes of peripheral blood leukocytes, neutrophils, platelets and hemoglobin before the start of the test (0d) and 1d, 3d, 5d, 7d, 10d, and 14d after the start of the test, as well as the severity of concurrent infections and antibiotic use Time, number of infusions of blood products.

Timeline

Start
2022-10-01
Primary completion
2024-09-01
Completion
2024-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject cord blood mononuclear cells Unknown 1e+08 cells Intravenous

Indications

No indication recorded.